These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 20727957)

  • 21. Conformational energetics of interpolyelectrolyte complexation between ι-carrageenan and poly(methylaminophosphazene) measured by high-sensitivity differential scanning calorimetry.
    Grinberg VY; Burova TV; Grinberg NV; Dubovik AS; Tur DR; Usov AI; Papkov VS; Khokhlov AR
    Langmuir; 2011 Jun; 27(12):7714-21. PubMed ID: 21612233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of drug release kinetics from hydroxypropyl methyl cellulose matrix tablets using polyvinyl pyrrolidone.
    Hardy IJ; Windberg-Baarup A; Neri C; Byway PV; Booth SW; Fitzpatrick S
    Int J Pharm; 2007 Jun; 337(1-2):246-53. PubMed ID: 17306477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parameters affecting the drug release from in situ gelling nasal inserts.
    Bertram U; Bodmeier R
    Eur J Pharm Biopharm; 2006 Jul; 63(3):310-9. PubMed ID: 16513333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of the critical points of HPMC hydrophilic matrices for controlled drug delivery.
    Miranda A; Millán M; Caraballo I
    Int J Pharm; 2006 Mar; 311(1-2):75-81. PubMed ID: 16446063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled release of clozapine through chitosan microparticles prepared by a novel method.
    Agnihotri SA; Aminabhavi TM
    J Control Release; 2004 Apr; 96(2):245-59. PubMed ID: 15081216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crystal growth formation in melt extrudates.
    Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended release of a large amount of highly water-soluble diltiazem hydrochloride by utilizing counter polymer in polyethylene oxides (PEO)/polyethylene glycol (PEG) matrix tablets.
    Kojima H; Yoshihara K; Sawada T; Kondo H; Sako K
    Eur J Pharm Biopharm; 2008 Oct; 70(2):556-62. PubMed ID: 18606223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation of an extended-release matrix tablet using chitosan/Carbopol interpolymer complex.
    Park SH; Chun MK; Choi HK
    Int J Pharm; 2008 Jan; 347(1-2):39-44. PubMed ID: 17662544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Encapsulation efficiency and controlled release characteristics of crosslinked polyacrylamide particles.
    Sairam M; Babu VR; Vijaya B; Naidu K; Aminabhavi TM
    Int J Pharm; 2006 Aug; 320(1-2):131-6. PubMed ID: 16766148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets.
    Schilling SU; Bruce CD; Shah NH; Malick AW; McGinity JW
    Int J Pharm; 2008 Sep; 361(1-2):158-68. PubMed ID: 18582547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro vs. canine data for assessing early exposure of doxazosin base and its mesylate salt.
    Erceg M; Vertzoni M; Cerić H; Dumić M; Cetina-Čižmek B; Reppas C
    Eur J Pharm Biopharm; 2012 Feb; 80(2):402-9. PubMed ID: 22019530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conformational changes in iota- and kappa-carrageenans induced by complex formation with bovine beta-casein.
    Burova TV; Grinberg NV; Grinberg VY; Usov AI; Tolstoguzov VB; Kruif CG
    Biomacromolecules; 2007 Feb; 8(2):368-75. PubMed ID: 17291059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of poloxamers on the dissolution performance and stability of controlled-release formulations containing Precirol ATO 5.
    Jannin V; Pochard E; Chambin O
    Int J Pharm; 2006 Feb; 309(1-2):6-15. PubMed ID: 16376034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble filler as a dissolution profile modulator for slightly soluble drugs in matrix tablets.
    Dvorácková K; Rabisková M; Masteiková R; Muselík J; Krejcová K
    Drug Dev Ind Pharm; 2009 Aug; 35(8):930-40. PubMed ID: 19274510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controlled release from bioerodible polymers: effect of drug type and polymer composition.
    Frank A; Rath SK; Venkatraman SS
    J Control Release; 2005 Feb; 102(2):333-44. PubMed ID: 15653155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liquisolid compacts: the effect of cosolvent and HPMC on theophylline release.
    Nokhodchi A; Aliakbar R; Desai S; Javadzadeh Y
    Colloids Surf B Biointerfaces; 2010 Aug; 79(1):262-9. PubMed ID: 20451361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the swelling behaviour of iota-carrageenan in monolithic matrix tablets.
    Kelemen A; Buchholcz G; Sovány T; Pintye-Hódi K
    J Pharm Biomed Anal; 2015 Aug; 112():85-8. PubMed ID: 25966465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pulse release of doxazosin from hydroxyethylcellulose compression coated tablet: mechanistic and in vivo study.
    Biswas N; Guha A; Sahoo RK; Kuotsu K
    Int J Biol Macromol; 2015 Jan; 72():537-43. PubMed ID: 25179280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controlled-release tablets from carrageenans: effect of formulation, storage and dissolution factors.
    Gupta VK; Hariharan M; Wheatley TA; Price JC
    Eur J Pharm Biopharm; 2001 May; 51(3):241-8. PubMed ID: 11343889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a diltiazem-lambda carrageenan complex.
    Bonferoni MC; Rossi S; Ferrari F; Bettinetti GP; Caramella C
    Int J Pharm; 2000 May; 200(2):207-16. PubMed ID: 10867250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.